A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above

NCT04841577 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

976

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSVPreF3 OA investigational vaccine
BIOLOGICAL: FLU-QIV

Sponsor

GlaxoSmithKline